ShangPharma opens pilot plant in Shanghai
For pharma development and cGMP manufacturing
The new multi-purpose pharmaceutical development and cGMP manufacturing facility will allow ShangPharma to support its clients Phase II and Phase III trials, expanding its service offering to include process and formulation r&d, analytical method development and validation, and cGMP manufacturing of intermediates and APIs.
Previously the CRO/CMO provided clients with materials for early discovery and GLP toxicology testing and Phase I clinical trials.
ShangPharma said it might further expand its manufacturing facilities if there is demand for commercial manufacturing of FDA- or EMEA-approved drugs.
The Fengxian facility will operate as a wholly owned subsidiary of the company under the name China Gateway Pharmaceutical Development Co. It includes a pilot plant that supports six separate bays with reactor capacities ranging from 200 to 3,000 litres and other speciality bays with reactor capacities ranging from 50 to 2000 litres for high temperature, cryogenics, highly toxic and pressurised reactions, including hydrogenation.
The company said there are also two cleanroom suites rated at Class 100,000 for isolation, 10 kilo-lab suites for bothnon-cGMP and cGMP manufacturing, as well as a large r&d laboratory for analytical, formulation and process development activities.
In addition, there are separate buildings for utilities, materials management, warehouse storage and waste water treatment with room for further expansion to support commercial manufacturing activities.
Testing of raw materials, intermediates and final products will be carried out at the site. An independent quality assurance department will ensure that materials are manufactured in accordance with cGMP requirements and that established standard operating procedures are followed, the firm said.
You may also like
Manufacturing
Micro Spargers improve Bioreactor yields
Read moreBiotech Fluidics has launched a range of micro spargers engineered to significantly reduce bubble size and increase gas transfer and volumetric mass transfer coefficient (kLa), resulting in reduced gas consumption and improved upstream reactor yields
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Micro Spargers improve Bioreactor yields
Biotech Fluidics has launched a range of micro spargers engineered to significantly reduce bubble size and increase gas transfer and volumetric mass transfer coefficient (kLa), resulting in reduced gas consumption and improved upstream reactor yields
Research & Development
University of Liverpool scientists unveil Novltex, a powerful new antibiotic against superbugs
The groundbreaking synthetic antibiotic is effective against multidrug-resistant bacteria such as MRSA and Enterococcus faecium, offering a promising new weapon in the global fight against antimicrobial resistance
Manufacturing
Kindeva launches new UK HQ and manufacturing hub to develop eco-friendly inhaler propellants
The new Loughborough facility will support drug development from early-stage analysis to commercialisation, helping the industry transition to low-GWP inhaler solutions whilst strengthening Kindeva’s global footprint
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Biocon Biologics wins FDA approval for Bosaya and Aukelso, denosumab biosimilars to Prolia and Xgeva
The approvals mark a major step in Biocon’s mission to deliver affordable, high-quality biologics, with Bosaya offering a cost-effective treatment for osteoporosis and Aukelso expanding access to oncology care for patients with bone-related complications